13.07.2015 Views

Biochemistry/Molecular Biology - ARVO

Biochemistry/Molecular Biology - ARVO

Biochemistry/Molecular Biology - ARVO

SHOW MORE
SHOW LESS

Create successful ePaper yourself

Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.

<strong>ARVO</strong> 2013 Annual Meeting Abstracts by Scientific Section/Group - <strong>Biochemistry</strong>/<strong>Molecular</strong> <strong>Biology</strong>previously described. Each of these proteins was chosen because theyrepresent crucial components of biochemical pathways involved inDR: inflammation, apoptosis, hypoxia and angiogenesis.Results: 4 of 33 measured proteins showed statistically significantdifferences between NPDR and PDR. These proteins were MatrixMetalloproteinase 9 (MMP-9) [p=.044, AUC=.7078], MatrixMetalloproteinase 14 (MMP-14) [p=.0122, AUC=.7062], VascularEndothelial Growth Factor 1175 (VEGF R2 Tyr1175) [p=.0088,AUC=.7024], and Bcl-2 thr56[(p=.0083, AUC=.7064]. All four ofthe same proteins were significantly up-regulated in NPDR versusPDR groups: MMP-9 (48.7%), MMP-14(32.9%), VEGF R2 Tyr1175(43.1%), & Bcl-2 thr 56 (33.4%). VEGF-A showed some upregulationbut fell short of statistical significance.Conclusions: Up-regulation of MMP-9, MMP-14, Activated VEGFR2 Tyr1175 and Bcl-2 thr 56 in PDR patients suggests a role in theconversion from NPDR to PDR. Hyperglycemia induced MMP-9activation stimulates apoptotic activity among pericytes, capillarycells and endothelial cells. It should be noted that studies haveimplicated these same biochemical markers during the transformationof many non-metastatic to metastatic cancers. This is the first timethat human vitreous samples have been sequentially sampled andinvestigated for proteomic changes along with clinical progression indifferent subsets of DR patients.Commercial Relationships: Joshua C. Hines, Ocular Proteomics(E); Stephanie M. Ecker, Ocular Proteomics LLC (E); Bert M.Glaser, Ocular Proteomics, LLC (E)Program Number: 1145 Poster Board Number: D0049Presentation Time: 1:00 PM - 2:45 PMCan Adiponectin be a Therapeutic Target for ProliferativeDiabetic Retinopathy?sulochana natarajan 1 , Subbulakshmi Chidambaram 1 , VidhyaSrinivasan 1 , Karthikka Palanisamy 1 , Pukhraj Rishi 2 , RadhakrishnanSelvi 1 . 1 <strong>Biochemistry</strong> and Cell <strong>Biology</strong>, Vision Research Foundation,Chennai, India; 2 Vitreoretinal, Medical Research Foundation,Chennai, India.Purpose: Adiponectin(APN) is a protein hormone havingantidiabetic and anti inflammatory properties. Its presence, in oculartissues, has been postulated, to have escaped from circulation due tothe dysfunctional BRB in retinal diseases. The purpose of this studyis to understand the origin of intraocular APN and its receptors,precisely measure vitreous APN in PDR and macular hole (MH),study its role in, in vitro angiogenesis and to screen small molecules,which can stimulate APN synthesis.Methods: All human studies were done with approval from IRB andconsent of the participants. Tissues derived from donor eye ballswere used for qPCR, immuno staining and western blot analysis.Vitreous samples were obtained from patients who underwentvitrectomy surgery for PDR and MH and used for APN measurementby ELISA. Human retinal endothelial cells (hREC), human choroidalendothelial cells (hCEC) and HUVEC were used for in vitroangiogenesis studies. Human adipocytes, hCEC and hREC were usedfor screening small molecules including amino acids and fatty acids,in order to select the one which stimulates APN secretion.Results: Expression of APN, AdipoR1 and AdipoR2 in retina,choroid, iris more specifically in the neural retina, photoreceptors,and endothelium was unambiguously identified by qPCR,immunostaining and western blot analysis. APN level in vitreous ofpatients with PDR (n=29) was found to be significantly (p

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!